Regencell Bioscience Holdings Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yat-Gai Au
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- First Commercial Building Causeway Bay Hong Kong KY1-1107
- IPO Date
- Jul 16, 2021
- CIK
- 0001829667
- Website
- regencellbioscience.com
- Similar Companies
- Business
- Regencell Bioscience Holdings Limited Regencell Bioscience Holdings Limited operates as an early-stage Traditional Chinese medicine (TCM) bioscience company focused on the research, development, and commercialization of liquid-based standardized TCM formulae for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD); the company offers three distinct formulae tailored for mild, moderate, and severe cases of ADHD and ASD patients, combining personalized natural herbs and compounds with modern scientific validation. Incorporated in 2014 and headquartered in Causeway Bay, Hong Kong, Regencell Bioscience Holdings Limited conducts its primary operations in Hong Kong, targeting patients, families, caregivers, and medical professionals with ongoing research studies and assistance programs limited to Hong Kong residents. In June 2025, the company executed a 38-for-1 forward stock split by capitalizing its share premium account, increasing outstanding ordinary shares to 494,488,908 as of June 30, 2025 without altering authorized capital or par value; it reported net losses of $3.58 million for fiscal 2025 amid continued R&D and administrative investments, with no approved products or commercial sales to date, and faced auditor emphasis on going concern risks alongside material weaknesses in internal controls.
RGC IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RGC
RGC FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RGC
RGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026
Deadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
RGC DEADLINE: Levi & Korsinsky Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline
Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGC
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
RGC INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026
DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
RGC DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGC
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell (RGC) Investors of Securities Class Action Deadline on June 23, 2026
RGC DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC
RGC DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC